Abstract
After injury to the central nervous system (CNS) of adult vertebrates, axonal regeneration is extremely limited because inhibitory proteins existing around the injury site prevent the regrowth of the lesioned axons. Previous studies have reported that several myelin-derived proteins (such as Nogo, MAG, OMgp) and developmental guidance proteins (such as RGM, semaphorin, ephrin) contribute to the inhibition of axonal regeneration after injury in the adult CNS. Although each neurite growth inhibitory protein induces neurite retraction and growth cone collapse through specific receptors, they commonly utilize the function of small GTPases, including Rho, Rac, Cdc42, and Ras, that regulate neurite outgrowth by controlling actin and microtubule cytoskeleton. The small GTPase Rho and its effector Rho-kinase play critical roles in the induction of neurite retraction and growth cone collapse in vitro and the inhibition of axonal regeneration in vivo. Therefore, the Rho inhibitor C3 transferase and Rho-kinase inhibitors are thought to be effective therapeutic candidates involved in the promotion of axonal regeneration after human CNS injuries such as spinal cord injury.
Keywords: Small GTPase, Rho, Rho-kinase, actin, microtubule, CNS injury, axonal regeneration
Central Nervous System Agents in Medicinal Chemistry
Title: Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Volume: 7 Issue: 4
Author(s): Mitsuharu Endo and Toshihide Yamashita
Affiliation:
Keywords: Small GTPase, Rho, Rho-kinase, actin, microtubule, CNS injury, axonal regeneration
Abstract: After injury to the central nervous system (CNS) of adult vertebrates, axonal regeneration is extremely limited because inhibitory proteins existing around the injury site prevent the regrowth of the lesioned axons. Previous studies have reported that several myelin-derived proteins (such as Nogo, MAG, OMgp) and developmental guidance proteins (such as RGM, semaphorin, ephrin) contribute to the inhibition of axonal regeneration after injury in the adult CNS. Although each neurite growth inhibitory protein induces neurite retraction and growth cone collapse through specific receptors, they commonly utilize the function of small GTPases, including Rho, Rac, Cdc42, and Ras, that regulate neurite outgrowth by controlling actin and microtubule cytoskeleton. The small GTPase Rho and its effector Rho-kinase play critical roles in the induction of neurite retraction and growth cone collapse in vitro and the inhibition of axonal regeneration in vivo. Therefore, the Rho inhibitor C3 transferase and Rho-kinase inhibitors are thought to be effective therapeutic candidates involved in the promotion of axonal regeneration after human CNS injuries such as spinal cord injury.
Export Options
About this article
Cite this article as:
Endo Mitsuharu and Yamashita Toshihide, Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/187152407783220788
DOI https://dx.doi.org/10.2174/187152407783220788 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interaction of Zinc Oxide/Green Tea Extract Complex Nanoparticles and its Effect on Monosodium Glutamate Toxicity in Liver of Rats
Current Pharmaceutical Biotechnology Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Biological Markers for Multiple Sclerosis
Current Medicinal Chemistry The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Autonomic Nervous System Alterations in Rett Syndrome
Current Pediatric Reviews Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Overview of Current Trends and the Future of Thromboprophylaxis in Orthopaedic Surgery
Vascular Disease Prevention (Discontinued) An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets L-Type Voltage-Dependent Calcium Channels As Therapeutic Targets for Neurodegenerative Diseases
Current Medicinal Chemistry Retraction Notice: Prevention of Emetic Episodes During Cesarean Delivery Performed Under Regional Anesthesia in Parturients
Current Drug Safety Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Controversies About the Chromosomal Stability of Cultivated Mesenchymal Stem Cells: Their Clinical Use is it Safe?
Current Stem Cell Research & Therapy Oxidative Stress and Drugs of Abuse: An Update
Mini-Reviews in Organic Chemistry